Topical administration of the secretome derived from human amniotic epithelial cells ameliorates psoriasis-like skin lesions in mice.

Abstract

BACKGROUND:

Psoriasis is a chronic inflammatory skin disease. Tissue stem cells have exhibited a therapeutic effect on psoriatic mice. However, the therapeutic effect of topical administration of the secretome derived from tissue stem cells on psoriasis has not been reported.

METHODS:

The secretome from human amniotic epithelial cells (AEC-SC) and human umbilical cord mesenchymal stem cells (UMSC-SC) was topically administrated on the back of imiquimod-induced psoriasis-like mice. Subsequently, we observed the skin lesions and skin inflammation of psoriasis-like mice. Next, we further analyzed the paracrine factors in AEC-SC and UMSC-SC by protein chips. Lastly, the effect of the crucial paracrine factor was investigated by imiquimod-induced psoriasis-like mice.

RESULTS:

We found that AEC-SC had a better therapeutic effect on attenuating psoriasis-like skin lesions including skin scales, skin redness and skin thickness than UMSC-SC, and it had a better regulatory effect on keratinocyte hyperproliferation and altered differentiation. Thus, we focused on AEC-SC. Further study showed that AEC-SC reduced the infiltration of neutrophils and interleukin-17-producing T cells. Next, the analysis of AEC-SC with protein chip revealed that the levels of anti-inflammatory factor interleukin-1 receptor antagonist (IL-1ra) were much higher in AEC-SC compared to that in UMSC-SC. More importantly, the beneficial effect of AEC-SC on psoriasis-like skin lesions and skin inflammation of mice were significantly impaired when neutralizing with IL-1ra antibody, while the recombinant human IL-1ra showed a less protective effect than AEC-SC.

CONCLUSIONS:

The present study demonstrated that AEC-SC could efficiently ameliorate psoriasis-like skin lesions and skin inflammation and IL-1ra plays an essential role. Therefore, topical administration of AEC-SC may provide a novel strategy for treating psoriasis-like inflammatory skin diseases.

• Authors: Mengbo Yang, Lanqi Wang, Zhimin Chen, Weijie Hao, Qian You, Jianhua Lin, Jingzhi Tang, Xin Zhao, Wei-Qiang Gao, Huiming Xu
• Journal: Stem cell research & therapy (Stem Cell Res Ther) Vol. 13 Issue 1 Pg. 393 (08 03 2022) ISSN: 1757-6512 [Electronic] England
• PMID: 35922852 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2022. The Author(s).

Chemical References

• Interleukin 1 Receptor Antagonist Protein
• Imiquimod

Topics

• Administration, Topical
• Animals
• Disease Models, Animal
• Humans
• Imiquimod
• Inflammation (chemically induced, therapy)
• Interleukin 1 Receptor Antagonist Protein (metabolism)
• Keratinocytes (metabolism)
• Mice
• Mice, Inbred BALB C
• Psoriasis (therapy)
• Secretome
• Skin (pathology)